Press "Enter" to skip to content

Aeterna Zentaris first one fourth revenues increase to $7.

That change outcomes from the periodic mark-to-market revaluation of currently outstanding share purchase warrants.12 per diluted and basic share, in comparison to $5.09 per basic and diluted share, for the same period this year 2010. This increase is mainly linked to higher net finance costs and higher income tax expense. Cash and money equivalents and short-term expenditure totalled $41.1 million as at March 31, 2011.. Aeterna Zentaris first one fourth revenues increase to $7.4 million Aeterna Zentaris Inc. First Quarter 2011 Highlights Agreement signed with Yakult Honsha Co. Ltd. for the development, manufacture and commercialization of perifosine, in Japan.5 million) upon achieving certain pre-established milestones, including medical and regulatory events in Japan, in addition to double-digit royalties on future net sales of perifosine in Japan.In this illusion, they are less inclined to truly educate themselves and keep the learning process evolving. Essentially, their arrogance prospects to ignorance. This is certainly the case for allopathic doctors, who feel their understanding is superior to others. They are less inclined to admit their knowledge gaps, preventing their self from learning further. This leads to uninformed decisions in medication, ultimately leading patients astray.

A new round of deficit talks begins amidst roadblocks, debt-ceiling concerns The way to handle entitlement spending issues including Medicare will be central to the discourse.